EPRX Valuation

Eupraxia Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

5.130

-0.06(-1.156%)1D

Overview
Forecast
Valuation
Earnings

EPRX Relative Valuation

EPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EPRX is overvalued; if below, it's undervalued.

Historical Valuation

Eupraxia Pharmaceuticals Inc (EPRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.27. The fair price of Eupraxia Pharmaceuticals Inc (EPRX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：5.13

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-59.99

P/B

Median3y

11.73

Median5y

8.58

-16.02

FCF Yield

Median3y

-22.55

Median5y

-25.98

Competitors Valuation Multiple

The average P/S ratio for EPRX's competitors is 1.96, providing a benchmark for relative valuation. Eupraxia Pharmaceuticals Inc Corp (EPRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

EPRX.O

Eupraxia Pharmaceuticals Inc

Loss

Average P/S: 1.96

184.46M